378746-64-6
378746-64-6 structure
- Name: Nemonoxacin
- Chemical Name: 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid
- CAS Number: 378746-64-6
- Molecular Formula: C20H25N3O4
- Molecular Weight: 371.43000
- Catalog: Signaling Pathways Anti-infection Bacterial
- Create Date: 2017-02-16 07:15:14
- Modify Date: 2024-01-07 09:44:24
-
Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia[1][2][3].
| Name | 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid |
|---|---|
| Synonyms |
Nemonoxacin
UNII-P94L0PVO94 |
| Description | Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
Bacterial[1][2][3]. |
| In Vitro | Nemonoxacin (0-5.51 µM; 24 h) shows good antibacterial activity in vitro[1]. Cell Viability Assay[1] Cell Line: MSSA, MRSA Concentration: 0-5.51 µM (0-2048 µg/mL) Incubation Time: 24 h Result: Inhibited MSSA and MRSA with MIC90 values of 0.12 and 4 µg/mL. |
| In Vivo | Nemonoxacin (p.o.; 15 min and 6 h after infection) shows potent and broad-spectrum in vivo activity against both Gram-positive (S. aureus, S. capitis, S. pneumonia and E. faecalis) and Gram-negative (E. coli) isolates[2]. Nemonoxacin (p.o.; 6, 12 and 24 h after infection) shows potent activities towards (2.5, 5, 10, 20 mg/kg) S. pneumonia 0613 (PRSP) and (10, 20, 40, 80 mg/kg) K. pneumonia 0607 infections in mouse pulmonary infection model[2]. Animal Model: CD-1 ICR mice (18-22 g; mouse systemic infection model)[2]. Dosage: 1.6-4.0 mg/kg (S. aureus and S. capitis infections), 2.4-10.0 mg/kg (S. pneumonia infections), 5.0-22.6 mg/kg (E. faecalis infections), 1.6-10.0 mg/kg (E. coli infections) Administration: Oral administration; 15 min and 6 h after infection Result: Showed the ED50s of 2.08, 2.59 and 2.52 mg/kg to against S. aureus ATCC 29213 (MSSA), S. aureus 0705 (MRSA) and S. capitis 0687 (levofloxacin-resistant MRSC), respectively. Animal Model: CD-1 ICR mice (18-22 g; mouse pulmonary infection model)[2]. Dosage: 2.5, 5, 10, 20 mg/kg (S. pneumonia 0613 (PRSP)); 10, 20, 40, 80 mg/kg (K. pneumonia 0607) Administration: Oral administration; 6, 12 and 24 h after infection Result: Significantly decreased colony counts in vivo. |
| Molecular Formula | C20H25N3O4 |
|---|---|
| Molecular Weight | 371.43000 |
| Exact Mass | 371.18500 |
| PSA | 97.79000 |
| LogP | 2.98200 |